Vector-borne Viruses in Turkey: A Systematic Review and Bibliography
Publication date: Available online 16 September 2020Source: Antiviral ResearchAuthor(s): Koray Ergünay, Ceylan Polat, Aykut Özkul
Publication date: October 2020Source: Antiviral Research, Volume 182Author(s):
Publication date: Available online 25 September 2020Source: Antiviral ResearchAuthor(s): Reiko Saito, Hidekazu Osada, Keita Wagatsuma, Irina Chon, Isamu Sato, Takashi Kawashima, Tadashi Saito, Naoki Kodo, Yasuhiko Ono, Yasushi Shimada, WintWint Phyu, Yugo Shobugawa
Authors: Kwo P, Dronamraju D PMID: 32967407 [PubMed - as supplied by publisher]
Publication date: Available online 24 September 2020Source: Antiviral ResearchAuthor(s): Ricardo Sanchez-Velazquez, Giuditta de Lorenzo, Rapeepat Tandavanitj, Chayanee Setthapramote, Peter J. Bredenbeek, Leonia Bozzacco, Margaret R. MacDonald, Jordan J. Clark, Charles M. Rice, Arvind H. Patel, Alain Kohl, Margus Varjak
Publication date: Available online 24 September 2020Source: Antiviral ResearchAuthor(s): Min Li, Lei Zhou, Harold G. Dorsey, Charles Musoff, Dereck Amakye Jnr, Natalie Schoen, Kweku Djan, Elijah Paintsil
Publication date: Available online 24 September 2020Source: Antiviral ResearchAuthor(s): Yaiza Fernández-García, Sebastiaan ter Horst, Marcella Bassetto, Andrea Brancale, Johan Neyts, Dominga Rogolino, Mario Sechi, Mauro Carcelli, Stephan Günther, Joana Rocha-Pereira
Condition: HBeAg Positive Chronic Hepatitis B Intervention: Drug: ETV+PegIFN-α Sponsor: Beijing 302 Hospital Not yet recruiting
Publication date: Available online 23 September 2020Source: Antiviral ResearchAuthor(s): Kyle L. O’Donnell, Diego A. Espinosa, Henry Puerta-Guardo, Scott B. Biering, James Schiltz, Matthew L. Nilles, Jeffrey Li, Eva Harris, David S. Bradley
Authors: Pokorska-Śpiewak M, Śpiewak M Abstract In recent years, significant progress in the antiviral treatment of chronic hepatitis C (CHC) has been made due to the development of interferon-free therapies. Three different highly effective, oral direct-acting antiviral (DAA) regimens have been approved for use in adolescents with CHC between the ages of 12-years-old and 17-years-old in Europe. According to the current recommendations, all treatment-naïve and treatment-experienced children with CHC virus infection should be considered for DAA therapy to prevent the possible progression of hepatitis C virus-...
This study aimed to investigate the absolute count of certain immune cell subsets in untreated HCV-infected patients compared to healthy subjects and during pegylated interferon- α and ribavirin (PegIFN/RBV) therapy. Materials and Methods: Sixty HCV genotype 4-infected patients were treated with PegIFN/RBV therapy for 52 weeks. Efficacy was measured by the early virologic response (EVR) at post-therapy. Absolute count of mature T, T helper, T cytotoxic, T activated, Natura l Killer (NK), Natural Killer/T (NKT), B, T regulatory cells (Treg) and T helper: T cytotoxic cells ratio were longitudinally analyzed by flow cyt...